Please use this identifier to cite or link to this item:
https://doi.org/10.1007/s13346-015-0240-4
Title: | A biodegradable ocular implant for long-term suppression of intraocular pressure | Authors: | Ng, X.W Liu, K.L Veluchamy, A.B Lwin, N.C Wong, T.T Venkatraman, S.S |
Keywords: | elastomer macrogol poly(lactide co caprolactone) timolol maleate unclassified drug antihypertensive agent delayed release formulation polymer timolol animal experiment animal model Article biocompatibility clinical examination controlled study disease course drug delivery system gel permeation chromatography glaucoma Haplorhini in vitro study in vivo study intraocular pressure lipophilicity mathematical model microfilm nonhuman ophthalmological implant priority journal sustained drug release administration and dosage animal biodegradable implant chemistry delayed release formulation drug effects drug release intraocular pressure Macaca fascicularis Ocular Hypertension therapeutic use Absorbable Implants Animals Antihypertensive Agents Delayed-Action Preparations Drug Delivery Systems Drug Liberation Intraocular Pressure Macaca fascicularis Ocular Hypertension Polymers Timolol |
Issue Date: | 2015 | Citation: | Ng, X.W, Liu, K.L, Veluchamy, A.B, Lwin, N.C, Wong, T.T, Venkatraman, S.S (2015). A biodegradable ocular implant for long-term suppression of intraocular pressure. Drug Delivery and Translational Research 5 (5) : 469-479. ScholarBank@NUS Repository. https://doi.org/10.1007/s13346-015-0240-4 | Rights: | Attribution 4.0 International | Abstract: | Timolol maleate (TM) has been used for many years for the reduction of intraocular pressure (IOP) in glaucoma patients. However, the topical mode of administration (eyedrops) is far from optimal because of the issues of low bioavailability, high drug wastage, and lack of patient compliance. Suboptimal control of the IOP leads to disease progression and eventually to blindness. Ideally, TM is delivered to the patient so that its action is both localized and sustained for 3 months or more. In this work, we developed a subconjunctival TM microfilm for sustained, long-term delivery of TM to the eyes, using the biodegradable elastomer poly(lactide-co-caprolactone) (PLC). The copolymer is biocompatible and has flexibility and mechanical characteristics suitable for a patient-acceptable implant. Controlling the release of TM for 3 months is challenging, and this work describes how, by using a combination of multilayering and blending with poly(ethylene glycol) (PEG) copolymers, we were able to develop a TM-incorporated biodegradable film that can deliver TM at a therapeutic dose for 90 days in vitro. The data was further confirmed in a diseased primate model, with sustained IOP-lowering effects for 5 months with a single implant, with acceptable biocompatibility and partial degradation. © 2015, The Author(s). | Source Title: | Drug Delivery and Translational Research | URI: | https://scholarbank.nus.edu.sg/handle/10635/183743 | ISSN: | 2190393X | DOI: | 10.1007/s13346-015-0240-4 | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1007_s13346-015-0240-4.pdf | 1.47 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License